Edaravone suspension for oral administration

MYPI2025002966A0Undetermined Publication Date: 2020-05-02TANABE PHARMA CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025002966
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-11-02
Filing Date
2019-11-01
Publication Date
2020-05-02
Patent Text Reader

Abstract

EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION ABSTRACT This invention provides with an edaravone suspension for oral administration having excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby.
Need to check novelty before this filing date? Find Prior Art